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Received 7 July 2006; received in revised form 19 December 2006; accepted 29 December 2006AbstractEnterohaemorrhagic Escherichia coli (EHEC) infections in humans are an important public health concern and are commonly
acquired via contact with ruminant faeces. Cattle are a key control point however cross-protective vaccines for the control of EHEC in
the bovine reservoir do not yet exist. The EHEC serogroups that are predominantly associated with human infection in Europe and
North America are O157 and O26. Intimin and EHEC factor for adherence (Efa-1) play important roles in intestinal colonisation of
cattle byEHECandare thus attractive candidates for thedevelopmentof subunit vaccines. Immunisationof calveswith the cell-binding
domain of intimin subtypes b or g via the intramuscular route induced antigen-specific serum IgG1 and, in some cases salivary IgA
responses, but did not reduce the magnitude or duration of faecal excretion of EHEC O26:H- (Int280-b) or EHEC O157:H7 (Int280-g)
upon subsequent experimental challenge. Similarly, immunisation of calves via the intramuscular route with the truncated Efa-1
protein (Efa-10) from EHECO157:H7 or a mixture of the amino-terminal and central thirds of the full-length protein (Efa-1-N andM)
did not protect against intestinal colonisation by EHECO157:H7 (Efa-10) or EHECO26:H- (Efa-1-N andM) despite the induction of
humoral immunity. A portion of the serum IgG1 elicited by the truncated recombinant antigens in calves was confirmed to recognise
native protein exposed on the bacterial surface. Calves immunisedwith amixture of Int280-g andEfa-1
0 or an EHECO157:H7 bacterin
via the intramuscular route then boosted via the intranasal route with the same antigens using cholera toxin B subunit as an adjuvant
were also not protected against intestinal colonisation by EHEC O157:H7. These studies highlight the need for further studies to
develop and test novel vaccines or treatments for control of this important foodborne pathogen.
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Enterohaemorrhagic Escherichia coli (EHEC) are
zoonotic enteric pathogens of worldwide importance.
Infections in humans may involve acute gastroenteritis
and be complicated by haemorrhagic colitis and severe
renal and neurological sequelae associated with the
production of one or more Shiga toxins. Antibiotic use
is contra-indicated in the treatment of such infections
and current therapy is mostly supportive. Ruminants are
an important reservoir of EHEC (Gansheroff and
O’Brien, 2000), and human infections are frequently
associated with direct contact with ruminants or their
environment (Locking et al., 2001; O’Brien et al.,
2001). Consumption of meat, rawmilk, vegetables, fruit
or water contaminated with ruminant faeces is also a
risk factor in sporadic cases of human EHEC infection
(Caprioli and Tozzi, 1998). In Europe and North
America EHEC infections are predominantly attributed
to serotype O157:H7, but infections with non-O157
EHEC (especially of serogroups O26, O103, O111 and
O118) are an emerging problem and indeed may be
more common than those caused by O157 in some
countries (Bettelheim, 2003). Stochastic simulation
models predict that cattle are a key control point to
reduce the incidence of EHEC infection in humans
(Jordan et al., 1999), however until recently the host and
bacterial factors influencing intestinal colonisation of
cattle by EHEC were poorly understood.
EHEC strains produce intimin, an outer membrane
adhesin encoded by the eae gene located in a
chromosomal pathogenicity island termed the locus
of enterocyte effacement (LEE; reviewed in Stevens and
Wallis, 2005). Intimin mediates intimate bacterial
attachment to enterocytes by binding to Tir, a bacterial
protein which is translocated into host cells by a LEE-
encoded type III secretion system. Intimin can also bind
in vitro to b1-integrins and cell-surface localised
nucleolin and these proteins can be detected proximal
to adherent EHEC O157:H7 in vivo (Sinclair et al.,
2006). Intimin is a key colonisation factor for EHEC
O157:H7 in neonatal calves (Dean-Nystrom et al.,
1998), young and weaned calves (Dean-Nystrom et al.,
1999; Vlisidou et al., 2006) and adult cattle and sheep
(Cornick et al., 2002). In addition, intimin influences the
carriage and virulence of EHEC O157:H7 in strepto-
mycin pre-treated mice (Judge et al., 2004), infant
rabbits (Ritchie et al., 2003) and gnotobiotic and
neonatal piglets (Donnenberg et al., 1993; Dean-
Nystrom et al., 1998).
Studies with single and double eae and tir mutants of
EHEC O157:H7 in calves and lambs have indicated thattir mutations are at least as attenuating as those
affecting eae, suggesting that the intimin–Tir interac-
tion, as opposed to binding of eukaryotic co-receptors,
is of key importance (Vlisidou et al., 2006). Serological
and phylogenetic analysis has identified at least six
distinct intimin subtypes (designated Int-a, b, g, d, e
and u) that vary in the sequence of the carboxy-terminal
cell-binding domain (Adu-Bobie et al., 1998; Oswald
et al., 2000; Zhang et al., 2002).
Although colonisation of calves by EHEC O157:H7
is intimin-dependent, EHEC O157:H7 (intimin subtype
g) has only been observed to form sparse microcolonies
at distal sites in the intestines of calves (caecum, colon
and rectum) with most bacteria being detected in the
luminal contents (van Diemen et al., 2005). By
comparison, in age-matched calves EHEC O26:H-
(intimin subtype b) can be observed to adhere in
extensive microcolonies at these sites, often covering
entire villi, despite being shed in comparable numbers
(van Diemen et al., 2005).
Intimin-specific antibodies can be detected in sera
from patients convalescing from severe EHEC infec-
tion (Jenkins et al., 2000; Li et al., 2000; Karpman et al.,
2002). Antibodies directed against the cell-binding
domain of intimin inhibit bacterial adherence to
cultured epithelial cells (McKee and O’Brien, 1996;
Gansheroff et al., 1999; Carvalho et al., 2005) and
porcine-intestinal explants (Girard et al., 2006).
Passively acquired intimin-specific antibodies also
confer protection, since neonatal piglets allowed to
suckle dams vaccinated intramuscularly with intimin-g
exhibit increased resistance to colonisation and
intestinal damage following experimental inoculation
with EHEC O157:H7 compared to piglets that suckled
mock-vaccinated dams (Dean-Nystrom et al., 2002).
Intimin-based subunit vaccines also confer protection
upon the recipient; mice primed parenterally with the
carboxyl-terminal portion of intimin-g then orally fed
transgenic intimin-g-expressing plant cells, generate
intimin-specific mucosal immune responses and shed
EHEC O157:H7 for a shorter duration than mock-
vaccinated animals (Judge et al., 2004). However,
intimin-specific responses may be subtype-specific
since immunisation of mice with the carboxyl-terminal
domain of intimin-a from EPEC O127:H6 induced
protection against a Citrobacter rodentium strain
engineered to express intimin-a, but not to wild-type
C. rodentium expressing intimin-b (Ghaem-Maghami
et al., 2001). While it has been shown that intranasal
immunisation of cattle with a carboxyl-terminal
64 kDa intimin polypeptide adjuvated with a low-
toxicity derivative of E. coli heat-labile toxin induces
P.M. van Diemen et al. / Veterinary Immunology and Immunopathology 116 (2007) 47–58 49antigen-specific serum IgG1 and salivary IgA (Yoko-
mizo et al., 2002), the protective efficacy of intimin-
based subunit vaccines in cattle has yet to be tested.
Another factor influencing colonisation of the bovine
intestines is EHEC factor for adherence (Efa-1). Non-
O157 EHEC, including serotype O26:H-, contain a full-
length copy of efa-1 while EHEC O157:H7 contains a
truncated form which is predicted to encode the amino-
terminal 433 amino acids of the protein (efa-10) (Perna
et al., 2001). Mutation of efa-1 in EHEC serotypes
O5:H- and O111:H- significantly reduced faecal
excretion and bacterial adherence to the colonic
epithelium in experimentally infected calves (Stevens
et al., 2002b). Antibodies directed against the central
and carboxyl-terminal portions of Efa-1 label the
bacterial surface and inhibit adherence of rabbit
enteropathogenic E. coli (EPEC) to cultured epithelial
cells and this may indicate that Efa-1 is an adhesin per
se (Badea et al., 2003). However, efa-1 mutations in
EHEC O5:H- and O111:H- indirectly impair the
expression and secretion of type III secreted proteins
encoded by the LEE that are known to influence
intestinal colonisation (Stevens et al., 2002b; Dziva
et al., 2004; van Diemen et al., 2005). Mutation of the
truncated efa-1 gene of EHEC O157:H7 impaired
adherence to cultured cells but did not significantly
impair intestinal colonisation of calves (Stevens et al.,
2004).
The aim of the present study was to assess the
protective efficacy of subunit vaccines comprising of
intimin and Efa-1 polypeptides against intestinal
colonisation of cattle by EHEC strains of serotypes
O157:H7 and O26:H- following parenteral and mucosal
immunisation. The protection conferred by a formalin-
inactivated EHEC O157:H7 bacterin was also assessed,
since inactivated vaccines are effective in the control of
other bacterial diseases including salmonellosis, pas-
teurellosis and coliform mastitis.
2. Materials and methods
2.1. Bacterial strains
EHEC O157:H7 strain EDL933 (stx1+, stx2+, eae-g)
was isolated in 1982 following an outbreak of
haemorrhagic colitis in the USA (Riley et al., 1983).
EHEC O26:H- strain 193 (stx1+, eae-b) was isolated in
1962 in the USA from a calf with diarrhoea (Mainil
et al., 1987). Strains EDL933nalR (Dziva et al., 2004)
and 193nalR (van Diemen et al., 2005) are spontaneous
nalidixic acid resistant derivatives of EDL933 and 193,
respectively, and exhibit normal growth and adhesioncharacteristics in vitro and efficiently colonise the
intestines of calves. Strain STM2H2 is a kanamycin
resistant derivative of 193nalR that is fully colonisation
proficient in calves (van Diemen et al., unpublished
data). E. coli K-12 strain BL21 (DE3) Star cells were
obtained from Novagen1 (Merck Biosciences Ltd.,
Nottingham, UK). Bacteria were routinely cultured
using Luria-Bertani (LB) medium supplemented with
the following antibiotics where appropriate: ampicillin
(Amp) 100 mg/ml; nalidixic acid (Nal) 25 mg/ml;
kanamycin (Km) 50 mg/ml. For oral inoculation
studies, bacterial strains were amplified in brain heart
infusion broth for 18 h at 37 8C with shaking.
2.2. Production and purification of recombinant
proteins
The portion of the eae gene that encodes the
carboxyl-terminal 280 amino acids of intimin was
amplified by polymerase chain reaction from EHEC
O26:H- strain 193 (Int280-b) and EHEC O157:H7 strain
EDL933 (Int280-g) using a conserved forward primer
(Int-LIC-for: 50-GAC GAC GAC AAG ATTACT GAG
ATT AAG GCT G-30) and subtype-specific reverse
primers (O26Int-LIC-rev: 50-GAG GAG AAG CCC
GGT TTA TTT TAC ACA AAC AG-30 and O157Int-
LIC-rev: 50-GAGGAGAAGCCC GGT TTATTC TAC
ACAAACCG-30). The products were cloned in pET30-
Ek/Lic (Novagen1) by a ligation-independent method
as amino-terminal 6His-S-tag fusions. The amino-
terminal and central portions of Efa-1 from EHEC
O111:H- strain E45035 (Efa-1-N, amino acids 1–993;
Efa-1-M, amino acids 994–1896) and the truncated
version of Efa-1 from E. coli O157:H7 (Efa-10) were
cloned in pET30-Ek/Lic as described elsewhere (Abu-
Median et al., 2006).
Proteins were expressed in E. coli K-12 strain BL21
(DE3) Star cells which lack RNaseE to stabilise mRNA.
The Overnight ExpressTM Autoinduction System I
(Novagen1) was used to induce Int280-g and Int280-b
expression. Cell extracts were prepared using BugBus-
ter1 (Novagen1) and the supernatant fraction mixed
with His-MagTM Agarose Beads (Novagen1) for
affinity purification of the Int280 proteins as described
by the manufacturer. Efa-1 proteins were expressed
under IPTG induction in E. coli BL21 (DE3) Star and
the proteins purified by affinity chromatography using
HIS-SelectTM Nickel Affinity Gel (Sigma, St. Louis,
MO, USA) under denaturing conditions. Bacterial cell
pellets were lysed by resuspension in 6 M guanidine
hydrochloride and cell debris was removed by
centrifugation. The supernatant was then equilibrated
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urea before applying to the affinity gel. Proteins were
eluted with 0.1 M sodium phosphate, pH 4.5, 8 M urea,
and dialysed against 200-fold volume pure water using
Slide-A-Lyzer cassettes (Pierce Biotechnology, Inc.,
Rockford, IL, USA) for 2 h at 4 8C. The yield, size,
stability and purity of the expressed proteins were
assessed by 4–15% SDS-PAGE and Western blotting
with Novagen1 monoclonal antibodies specific to the
6His tag according to manufacturer’s instructions.
Protein concentrations were determined by the BCA
method (Pierce Biotechnology, Inc.).
2.3. Vaccines and adjuvants
For intramuscular vaccinations (i.m.), Int280 and Efa-
1 polypeptides were formulated in an aluminium
hydroxide oil-based adjuvant (Alu-Oil; Intervet Inter-
national BV, Boxmeer, The Netherlands) at 100 mg
protein/dose. The mock (water) vaccine and an EHEC
O157:H7 bacterin were also formulated in Alu-Oil. The
bacterin consisted of formalin-inactivated EDL933nalR
grown statically for 6 h at 37 8C in a 5% CO2
atmosphere in Dulbecco’s Modified Essential Medium
supplemented with 10% (v/v) foetal calf serum and
25 mM HEPES (3.9  109 cells/dose). These condi-
tions are known to activate the expression of LEE-
encoded proteins. The vaccines (2 ml) were delivered at
a single site in the neck muscle.
For intranasal immunisations (i.n.), the relevant
proteins (500 mg/dose) were mixed with cholera toxin B
subunit (CT-B 100 mg/dose, Sigma) as a mucosal
adjuvant. CT-B is known to potentiate immune
responses against co-administered antigens in a variety
of model systems (Rappuoli et al., 1999; Douce et al.,
1997). The bacterin was mixed at 1010 cells/dose with
100 mg/dose CT-B. A syringe fitted with a device to
create a fine aerosol was inserted as far as possible into
the nostril and 2.5 ml of the solution was delivered into
each nostril during inhalation.
2.4. Vaccination and challenge model
All animal experiments were performed in accor-
dance with the Animals (Scientific Procedures) Act
1986 and were approved by the local Ethical Review
Committee. Calves were housed in individual pens on
straw and fed on milk replacer with free access to water,
hay and weaner pellets. Two days before oral challenge
the calves were transferred to security containment level
3 accommodation and housed in pens on shavings.
Animals were monitored for EHEC prior to eachimmunisation and challenged by direct plating of faeces
on Sorbitol MacConkey agar (Oxoid, Basingstoke, UK)
containing 2.5 mg/ml potassium tellurite (T-SMC). It is
acknowledged that T-SMC may not detect all EHEC,
however, it is generally effective for the selection of the
predominant serogroups O157 and O26. Presumptive
EHEC colonies were screened for the presence of stx1,
stx2 and eae genes by colony PCR as described
elsewhere (Stevens et al., 2004). Calves excreting
EHEC or in generally poor health status were excluded
from the study.
Established calf oral inoculation models using
EDL933nalR (Dziva et al., 2004) and 193nalR (van
Diemen et al., 2005) were used with minor modifica-
tions. In Trial 2, it was necessary to use a kanamycin-
resistant derivative of strain 193nalR (STM2H2) owing
to a background of endogenous nalidixic acid and
tellurite resistant (stx1, stx2, eae negative) bacteria in
some of the calves. In total, 3 trials were performed with
12, 14-day-old conventional Friesian bull calves in each
trial.
In Trial 1, on day 0 (14  1 days old) and day 28
calves were vaccinated i.m. with Int280-g (n = 4), Efa-1
0
(n = 4) or mock (n = 4), followed on day 42 by oral
challenge with 2.9  0.78  1010 colony forming units
(CFU) of EHEC O157:H7 strain EDL933 nalR.
In Trial 2, calves (14  1 days old) were vaccinated
i.m. with either Int280-b (n = 4), a mixture of Efa-1-N
and M (n = 4; 100 mg/dose each), or mock (n = 4) on
days 0 and 28, followed on day 42 by oral challenge
with 2.8  0.67  1010 CFU EHEC O26:H- strain
STM2H2.
In Trial 3, calves (13  1 days old) were vaccinated
i.m. with a mixture of Efa-10 and Int280-g (n = 4;
100 mg/dose each), EHEC O157 bacterin (n = 4) or
mock (n = 4), on days 0 and 28, combined with i.n.
vaccination on days 28 and 42. The calves were
challenged on day 56 with 1.93  0.78  1010 CFU
EDL933nalR.
After challenge, viable EHEC per gram of faeces
were enumerated twice daily for at least 14 days post-
inoculation by plating triplicate 10-fold serial dilutions
of faeces onto T-SMC medium containing 25 mg/ml
nalidixic acid (EDL933nalR-challenged animals) or T-
SMC-Nal medium containing 50 mg/ml kanamycin
(strain 193nalR-STM2H2 -challenged animals). The
sensitivity of detection was 102 CFU/g.
2.5. Immune parameters
Venous blood and saliva samples were collected
before each vaccination and before challenge to monitor
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immunosorbent assays (ELISA) were developed to
detect serum IgG1 and salivary IgA antibodies to
intimin and Efa-1 polypeptides, CT-B and O157
lipopolysaccharide (LPS). For this purpose, 96-well
microtiter plates (F96 Maxisorp, Nunc, Denmark) were
coated overnight at 4 8C with 100 ml/well of 100 mg/ml
of purified histidine-tagged recombinant protein (Int280-
g, Int280-b, Efa-1
0, Efa-1-N, Efa-1-M), 1 mg/ml CT-B or
0.5 mg/ml LPS of EHEC O157:H7 in Carbonate buffer
(pH 9.6). Pre-determined sample dilutions (serum
1:640, saliva 1:10) were added to the antigen-coated
wells. After incubation for 1 h at room temperature and
subsequent washing, wells were incubated with horse-
radish peroxidase-conjugated sheep anti-bovine IgG1
(1:5000, Serotec, Oxford, UK) for 1 h at room
temperature. After further washing, tetramethylbenzi-
dine substrate (TMB, Sigma, St. Louis, MO, USA) was
added. Colour formation was stopped after 10 min with
2.5N sulphuric acid. The optical density was measured
at 450 nm (OD450) with background correction of
620 nm.
In pilot experiments to assess cross-reactivity (e.g.
responses of Int280-g-vaccinated animals to Efa-1
0) it
became apparent that a component of the responses
detected by ELISA was specific to the affinity tag or
contaminants from the E. coli expression host. Thus the
serum samples were pre-adsorbed against an irrelevant
protein (the major fimbrial subunit of EHEC O157:H7
F9 fimbriae) expressed from pET30/EkLIC with the
same affinity tag in the same E. coli host as described
(Low et al., 2006). This step abolished cross-reactivity
and ensured that the responses measured were against
the biologically relevant portion of the antigens used.
Western blotting assays using purified proteins were
performed to confirm the specificity of the responses
measured in the ELISA. In order to confirm that serum
antibodies raised in calves vaccinated with the truncated
recombinant proteins could bind to native protein,
ELISAs were performed with sera of representative
calves, essentially as above, using whole bacterial cells
(wild type and Deae or Defa-1 strains) and sera pre-
adsorbed on Deae- or Defa-1 mutants. Briefly, E. coli
O157:H7 strain 85–170nalR and its isogenic Deae
mutant (Vlisidou et al., 2006), and rabbit EPEC strain
83/89 (known to express native Efa-1) and its isogenic
efa-1 mutant (Badea et al., 2003), were separately
inoculated into DMEM supplemented with 25 mM
HEPES buffer and incubated statically at 37 8C for 6 h.
Bacteria were killed and fixed by addition of 0.5% (v/v)
formalin, then harvested by centrifugation and stan-
dardized for the ELISA as described by Zhu et al.(2006). Sera were pre-adsorbed for 1.5 h at 37 8C on a
rolling platform.
2.6. Statistical analysis
Data on faecal shedding and antibody response were
statistically analysed for effect of vaccination by means
of an F-test, with the data taken as repeated
measurements (Proc Mixed, SAS, 1995). Bacterial
recoveries were analysed after a 10log transformation.
Differences were considered significant when P < 0.05.
Subsequently, pairwise comparisons were performed at
the overall 0.05 level of significance. Where relevant,
relationships between the bacterial recoveries and
immune parameters were orthogonally fitted by poly-
nomial regression using Proc Mixed and Proc GLM
(SAS, 1995).
3. Results
3.1. Trial 1: i.m. vaccination of calves with Int280-g
or Efa-10 induces antigen-specific serum IgG but
does not confer protection against intestinal
colonisation by EHEC O157:H7
All vaccinated calves mounted a significant
(P < 0.05) antigen-specific serum IgG1 response to
the protein with which they were vaccinated (Fig. 1A
and B). Sero-conversion was not detected in mock-
immunised animals.
Three calves (1 Efa-10 and 2 Int280-g vaccinated) had
antibodies recognising Int280-g at the beginning of the
experiment. On day 28 these antibodies were no longer
detectable suggesting that they were maternal in origin.
The response of the Int280-g-vaccinated calves sig-
nificantly increased to day 42 while the response of the
Efa-10 vaccinated calf remained low, indicating that
maternal antibody may have been present. One Int280-g-
vaccinated calf did not significantly respond and the
reasons for this are unclear.
The specificity of the responses was confirmed by
Western blotting. The serum samples recognised
proteins of the expected size and the intensity of
staining increased with boosting as expected given the
magnitude of the response detected by ELISA (data not
shown).
Antigen-specific salivary IgA was not observed in
calves immunised with Int280-g or Efa-1
0 (data not
shown).
Calves were challenged 2 weeks after the second
vaccination (day 42) with 2.9  0.78  1010 CFU per
calf of EDL933nalR. No significant differences in the
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Fig. 1. Serum IgG1 responses (mean  S.E.M.) to Int280-g (A) and Efa-10 (B). Course of faecal excretion (mean  S.E.M.) of EHEC O157:H7
strain EDL933nalR following oral challenge of calves immunised i.m. with Int280-g, Efa-1
0 or mock-antigen (C). Serum antibodies were confirmed to
bind native intimin-g by ELISA using whole cells (wild type andDeae strains) and serum preabsorbed on E. coliO157:H7Deae (D). Different letters
(a and b) indicate pairwise significant difference (P < 0.05) within a testdate. Same letters but with an accent (0) indicate pairwise tendency towards
significant difference (P < 0.1) within a testdate.magnitude or duration of faecal excretion were
observed between the groups (Fig. 1C). The low
responder calf shed comparable numbers of bacteria
to other Int280-g-vaccinated animals and those given
mock antigen. Serum IgG1 from representative Int280-
g-vaccinated calves was preadsorbed on an E. coli
O157:H7 Deae mutant and its reactivity against
whole cells of wild type and Deae mutant E. coli
O157:H7 measured by ELISA. Consistently lower
reactivity was observed against cells lacking intimin,
indicating that a portion of the serum IgG1 elicited by
the truncated recombinant antigen recognises
native intimin in the surface of E. coli O157:H7
(Fig. 1D).
3.2. Trial 2: i.m. vaccination of calves with Int280-b
or a mixture of Efa-1-N and M induces antigen-
specific serum IgG1 but does not confer protection
against intestinal colonisation by EHEC O26:H-
All vaccinated calves mounted a serum IgG1
response to the antigens used (Fig. 2A–C). The response
against Int280-b and Efa-1-N was significantly
(P < 0.05) higher than that of the mock vaccinated
calves from day 28 onwards. The response to Efa-1-Mwas raised in the Efa-1 vaccinated calves on day 42
(P < 0.06) as compared with the mock calves. Pre-
adsorption of the sera using his-tagged F9 protein
expressed in E. coli as described in Section 2.5
significantly lowered, but did not completely abrogate
the response of Int280-b vaccinated calves to Efa-1-N
and M in this experiment.
Int280-b induced salivary IgA responses were
significantly (P < 0.001) higher than those raised by
mock-vaccinated animals on day 42. The salivary IgA
responses to the Efa-1 polypeptides in animals
immunised with Efa-1-N and M were not significantly
different to controls (data not shown).
All calves were challenged 2 weeks after the second
vaccination (day 42) with 2.8  0.67  1010 CFU per
calf of strain STM2H2. No significant differences in the
magnitude or duration of faecal excretion were
observed between the groups (Fig. 2D).
Serum IgG1 from representative calves vaccinated
with Efa-1-N and M was preadsorbed on a rabbit EPEC
efa-1 mutant and its reactivity against whole cells of
wild type and efa-1 mutant bacteria measured by
ELISA. Lower reactivity was observed against cells
lacking Efa-1 (Fig. 2E), suggesting the presence of
antibodies able to recognise native protein.
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Fig. 2. Serum IgG1 responses (mean  S.E.M.) to Int280-b (A), Efa1-N (B) and Efa1-M (C). Course of faecal excretion (mean  S.E.M.) of EHEC
O26:H- strain STM2H2 following oral challenge of calves immunised i.m. with Int280-b, a mixture of Efa1-N and M, or mock-antigen (D). Serum
antibodies were confirmed to bind native Efa-1 by ELISA usingwhole cells (wild type and efa-1 strains) and sera preadsorbed on a rabbit EPEC efa-1
mutant (E). Different letters (a and b) indicate pairwise significant difference (P < 0.05) within a testdate. Same letters but with an accent (0) indicate
pairwise tendency towards significant difference (P < 0.1) within a testdate.3.3 i.m. Priming of calves with a mixture of Int280-g
and Efa-10 or an EDL933nalR bacterin followed by
intranasal boosting does not confer protection
against intestinal colonisation by EHEC O157:H7
As administration of an intimin polypeptide via the
intranasal route induces high titre serum IgG and
salivary IgA responses in cattle (Yokomizo et al., 2002),
we sought to determine if boosting parenterally primed
animals via the intranasal route would improve immune
responses and confer protection.
The Int280-g/Efa-1
0 vaccinated calves mounted
significantly higher (P < 0.001) serum IgG1 responses
against Int280-g and Efa-1
0 than the mock (Fig. 3A and
B). The combined i.n./i.m. immunisation appeared to
boost the anti-intimin IgG1 as compared with the resultsof Trial 1 (Fig. 1A). No further increase in IgG1 titre
was observed following the final intranasal only
immunisation.
The EDL933nalR bacterin elicited significantly
elevated IgG1 responses against Int280-g on day 56
(P < 0.05; Fig. 3A) and against lipopolysaccharide
(LPS) from EHEC O157:H7 from day 28 onwards
(P < 0.001; Fig. 3C). The bacterin did not induce an
IgG1 response to Efa-10 (Fig. 3B).
Salivary IgA responses against Int280-g and Efa-1
0
were significantly higher in animals given the recom-
binant proteins than in mock-vaccinated animals on day
42. However, on day 56 the response of the controls
were similar to those of the vaccinated calves (data not
shown). No difference in salivary IgA were observed
against LPS (data not shown).
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Fig. 3. Serum IgG1 responses (mean  S.E.M.) to Int280-g (A), Efa-10 (B) or EHEC O157 LPS (C). Course of faecal excretion (mean  S.E.M.) of
EHEC O157:H7 strain EDL933nalR following oral challenge of calves primed i.m. with a mixture of Int280-g and Efa-1
0, formalin-inactivated
EDL933 nalR or mock-antigen, then boosted with the same antigens intranasally (D). Different letters (a and b) indicate pairwise significant
difference (P < 0.05) within a testdate.The intranasal adjuvant CT-B increased the salivary
IgA response as compared with the before-intranasal-
vaccination samples in all calves including the mock
calves (Fig. 4A). Also a pronounced serum IgG1
response was detected (Fig. 4B) indicating that the
vaccines were effectively delivered and recognised by
the intranasal route.
Calves were challenged two weeks after the final
immunisation with 1.93  0.78  1010 CFU per calf of
EDL933nalR. No significant differences in the magni-
tude or duration of faecal excretion between the groups
were observed (Fig. 3D).Fig. 4. Salivary IgA (A) and serum IgG1 (B) responses (mean  S.E.M.) ag
pairwise significant difference (P < 0.05) within a testdate. Same letters b
difference (P < 0.1) within a testdate.4. Discussion
Vaccination is one of several options for the control of
enterohaemorrhagic E. coli in ruminants (reviewed in
Stevens et al., 2002a). Few trials using rationally
designed EHEC vaccines have been undertaken and to
our knowledge the efficacy of whole-cell inactivated
vaccines has not been assessed. Targeted and signature-
tagged mutagenesis of bacterial genes has offered
valuable insights into the molecular mechanisms
influencing intestinal colonisation of cattle by EHEC
and it is clear that proteins encoded by the LEE play keyainst the intranasal adjuvant CT-B. Different letters (a and b) indicate
ut with an accent (0) indicate pairwise tendency towards significant
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Both the LEE-encoded adhesin intimin and the LEE-
encoded type III secretion apparatus are known to be
important in calves (Dean-Nystrom et al., 1998, 1999;
Cornick et al., 2002;Dziva et al., 2004; vanDiemen et al.,
2005; Vlisidou et al., 2006). A vaccine based on the
secreted fraction of EHEC O157:H7 induced humoral
responses against key type III secreted proteins, aswell as
potent anti-lipopolysaccharide responses, and reduced
the numbers of EHEC O157:H7 shed in the faeces, the
number of animals shedding and the duration of shedding
following experimental inoculation of calves (Potter
et al., 2004). Vaccination also significantly (P = 0.04)
reduced the prevalence of EHEC O157:H7 in a small
scale trial using naturally exposed feedlot cattle (Potter
et al., 2004). Avaccine derived from a tir deletionmutant
was described as less efficacious than a preparation from
thewild-type vaccine suggesting that disrupting intimin–
Tir interactions may be fruitful (Potter et al., 2004).
However, in subsequent trials in 218pens of feedlot cattle
in 9 feedlots in Alberta and Saskatchewan there was no
significant association (P = 0.20) between vaccination
with EHEC O157:H7 secreted proteins and pen
prevalence of faecal EHEC O157:H7 following vaccina-
tion or prior to slaughter (van Donkersgoed et al., 2005).
These studies have re-invigorated efforts to develop
effective and cross-protective vaccines for the control of
EHEC.
The potential of intimin-based subunit vaccines was
suggested following observations that antibodies against
the carboxy-terminal domain inhibit bacterial adherence
(McKee and O’Brien, 1996; Gansheroff et al., 1999;
Carvalho et al., 2005; Girard et al., 2006). Subsequent
studies in murine and porcine models have indicated that
such vaccines reduce intestinal colonisation by EHEC to
some extent, albeit that protection may only be subtype-
specific if the variable cell-binding domain is used
(Ghaem-Maghami et al., 2001; Dean-Nystrom et al.,
2002; Judge et al., 2004). Immunisation of mice with the
conserved domain of intimin (Int388–667) proved to be
ineffective in a rodent model (Ghaem-Maghami et al.,
2001), therefore intimin-based vaccines may need to be
multivalent if they are to confer broad protection. Here,
we have observed that while polypeptides based on the
carboxyl-terminal domains of intimin-b andg can induce
serum IgG1 responses and variable salivary IgA
responses when administered via the parenteral and
mucosal routes, the responses do not confer protection
against EHEC strains expressing homologous intimin
types. The ability to induce humoral responses against
intimin in cattle is consistent with the observations of
Yokomizo et al. (2002), however to our knowledgewe arethe first to report the lack of efficacy of such responses in
cattle.
While we were able to detect humoral responses
against Efa-1 polypeptides, the biological activity of
such antibodies is less well understood. Mutation of
efa-10 in EHEC O157:H7 was recently found to reduce
bacterial adherence to cultured cells but had no
significant effect on intestinal colonisation of calves
and lambs (Stevens et al., 2004). This may partially
explain the paucity of protection against EHEC
O157:H7 infection that was conferred by this factor.
While mutation of full-length Efa-1 in non-O157
EHEC does markedly impair persistence in calves
(Stevens et al., 2002b), debate continues as to whether
Efa-1 acts an adhesin per se in such strains or whether
the attenuation reflects pleiotropic effects on
the expression and secretion of LEE-encoded
proteins.
Boosting of parenterally primed animals via the
intranasal route further increased serum IgG1 responses
to Int280-g. Disappointingly, while salivary IgA
responses against Int280-g and Efa-1
0 were significantly
higher than controls at day 42 (after combined
intranasal and intramuscular dosing on day 28), the
responses on day 56 (after intranasal only immunisation
on day 42) were not significantly greater than controls
due to an increased response by the mock animals. The
increase in salivary IgA titres over time was thought to
be due to the relatively low specificity of IgA, which
could be induced by a variety of other antigens
encountered during the period. The extent to which
mucosal immunisation was successful is therefore
difficult to assess. The adjuvant cholera toxin B subunit
(CT-B) induced potent serum IgG1 and salivary IgA
responses in all (mock) vaccinated animals and was
exclusively delivered via the intranasal route, indicating
that opportunity existed for the co-administered
antigens to have been recognised.
An inactivated vaccine comprising of formalin-
killed EHEC O157:H7 strain EDL933nalR proved to be
ineffective when administered by the combined
parenteral and mucosal regime, despite efficient
induction of anti-LPS and anti-Int280-g IgG1 responses.
The bacteria were cultured under conditions known to
activate expression of LEE-encoded proteins and
incubated under static conditions to preserve fimbriae,
EspA filaments and other surface-anchored molecules.
At this stage we cannot preclude the possibility that
such preparations may be effectivewhen prepared under
other conditions, when delivered by different routes or
when tested against different challenge doses and/or
natural exposure.
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the present studies reflects the high challenge doses used.
However, our oral inoculation models have reliably
detected the attenuating effect of mutations affecting
Efa-1 (Stevens et al., 2002b), the LEE-encoded type III
secretion system (Dziva et al., 2004; van Diemen et al.,
2005), F9 fimbriae (Dziva et al., 2004) and intimin–Tir
interactions (Vlisidou et al., 2006), despite using
comparable inoculum sizes. Vaccinated animals shed
similar numbers of organisms and for the same duration,
even during substantial periods of the experiment when
the number of organisms being shed was relatively low.
The model was selected since challenge doses of
107 CFU of EDL933nalR or 193nalR administered to
duplicate naı¨ve calves of the age to be used after
vaccination (ca. 10 weeks old), failed to establish
persistent infections (data not shown).
It is possible that the truncated recombinant antigens
did not confer protection because they failed to induce
high titres of antibody able to bind native surface-
exposed intimin or Efa-1 and neutralise its activity.
ELISA measurements using sera from calves vacci-
nated with Int280-g or a mixture of Efa-1-N and M
confirmed that a portion of the serum IgG1 response
was able to recognise native protein on bacterial
surfaces (Figs. 1D and 2E). The specificity of the
response induced induced by Int280-b was not tested as
an EHEC O26:H- Deae mutant strain was not available.
It is well established that in some cases effective
immunity may be generated after infection but not after
vaccination with purified inert molecules. This implies
that there are aspects of the infectious process itself that
initiate and/or potentiate the immune response. How-
ever, prior infection of calves with EHEC does not
appear to confer protection against re-infection (John-
son et al., 1996;Wray et al., 2000) and responses against
LEE-encoded proteins are weak or absent in experi-
mentally infected and naturally colonised animals (van
Diemen et al., unpublished observations). However, oral
dosing of mice with intimin expressed in transgenic
plant cells markedly potentiates humoral responses and
confers protection in mice previously vaccinated with
intimin by the intraperitoneal route (Judge et al., 2004).
Thus, it remains possible that the antigens used herein
may be suitable for immunisation of cattle provided
appropriate exposure to the intestinal immune system
can be achieved.
5. Conclusion
A whole cell-inactivated vaccine and subunit
vaccines based on intimin and Efa-1 polypeptidesinduced serum IgG and variable salivary IgA responses
following parenteral immunisation of cattle. Such
responses did not confer significant resistance to
intestinal colonisation by EHEC strains expressing
the homologous antigens, even after boosting of such
animals by the mucosal route.
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